Effect of Alpha-Lipoic Acid Supplementation on the Incidence of Postoperative Atrial Fibrillation in Cardiac Surgery Patients

• Status: Recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

ALA is administered orally since it is without difficulty absorbed in the stomach. ALA goes through the blood brain barrier and does not show toxic effects and actions at doses used for prophylactic and therapeutic purposes. This has encouraged us to use an efficient anti-oxidant and anti-inflammatory agent, alpha-lipoic acid (biochemical) as a relevant option to prevent POAF.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Thioctic Acid

Criteria

Inclusion Criteria:

• I

• Male or female patients above 18 years of age who are scheduled for cardiac surgery.

Exclusion Criteria:

• Any urgent or emergency surgery.

• Poor Left ejection volume (EF < 30%).

• Intake of steroids or any antiarrhythmic drugs except beta blockers during the last month before surgery

• Unable or unwilling to provide informed written consent.

• Pregnancy or lactation

• Known hypersensitivity to the study drug.

• Current treatment with antioxidants or alpha-lipoic acid for any indication.

• Infection or inflammatory disease except coronary artery disease.

• Left atrium size >70 mm.